Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentric, Proof-of-concept Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

NCT05255133 is registered in ClinicalTrials.gov with Universiteit Antwerpen as lead sponsor.

NCT NCT05255133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05255133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentric, Proof-of-concept Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
Lead sponsor
Universiteit Antwerpen
Phase
Not applicable
Overall status
Completed
Start date
October 9, 2017
Completion date
June 23, 2022
Enrollment
22 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors